Cargando…

Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin

Survivin is responsible for cancer progression and drug resistance in many types of cancer. YM155 selectively suppresses the expression of survivin and induces apoptosis in cancer cells in vitro and in vivo. However, the mechanism underlying these effects of YM155 is unknown. Here, we show that a tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Naoto, Yamauchi, Tomohiro, Hiramoto, Masashi, Yuri, Masatoshi, Naito, Masanori, Takeuchi, Masahiro, Yamanaka, Kentaro, Kita, Aya, Nakahara, Takahito, Kinoyama, Isao, Matsuhisa, Akira, Kaneko, Naoki, Koutoku, Hiroshi, Sasamata, Masao, Yokota, Hiroyuki, Kawabata, Shigeki, Furuichi, Kiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society for Biochemistry and Molecular Biology 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394938/
https://www.ncbi.nlm.nih.gov/pubmed/22442257
http://dx.doi.org/10.1074/mcp.M111.013243
_version_ 1782237909366079488
author Nakamura, Naoto
Yamauchi, Tomohiro
Hiramoto, Masashi
Yuri, Masatoshi
Naito, Masanori
Takeuchi, Masahiro
Yamanaka, Kentaro
Kita, Aya
Nakahara, Takahito
Kinoyama, Isao
Matsuhisa, Akira
Kaneko, Naoki
Koutoku, Hiroshi
Sasamata, Masao
Yokota, Hiroyuki
Kawabata, Shigeki
Furuichi, Kiyoshi
author_facet Nakamura, Naoto
Yamauchi, Tomohiro
Hiramoto, Masashi
Yuri, Masatoshi
Naito, Masanori
Takeuchi, Masahiro
Yamanaka, Kentaro
Kita, Aya
Nakahara, Takahito
Kinoyama, Isao
Matsuhisa, Akira
Kaneko, Naoki
Koutoku, Hiroshi
Sasamata, Masao
Yokota, Hiroyuki
Kawabata, Shigeki
Furuichi, Kiyoshi
author_sort Nakamura, Naoto
collection PubMed
description Survivin is responsible for cancer progression and drug resistance in many types of cancer. YM155 selectively suppresses the expression of survivin and induces apoptosis in cancer cells in vitro and in vivo. However, the mechanism underlying these effects of YM155 is unknown. Here, we show that a transcription factor, interleukin enhancer-binding factor 3 (ILF3)/NF110, is a direct binding target of YM155. The enhanced survivin promoter activity by overexpression of ILF3/NF110 was attenuated by YM155 in a concentration-dependent manner, suggesting that ILF3/NF110 is the physiological target through which YM155 mediates survivin suppression. The results also show that the unique C-terminal region of ILF3/NF110 is important for promoting survivin expression and for high affinity binding to YM155.
format Online
Article
Text
id pubmed-3394938
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher The American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-33949382012-07-16 Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin Nakamura, Naoto Yamauchi, Tomohiro Hiramoto, Masashi Yuri, Masatoshi Naito, Masanori Takeuchi, Masahiro Yamanaka, Kentaro Kita, Aya Nakahara, Takahito Kinoyama, Isao Matsuhisa, Akira Kaneko, Naoki Koutoku, Hiroshi Sasamata, Masao Yokota, Hiroyuki Kawabata, Shigeki Furuichi, Kiyoshi Mol Cell Proteomics Research Survivin is responsible for cancer progression and drug resistance in many types of cancer. YM155 selectively suppresses the expression of survivin and induces apoptosis in cancer cells in vitro and in vivo. However, the mechanism underlying these effects of YM155 is unknown. Here, we show that a transcription factor, interleukin enhancer-binding factor 3 (ILF3)/NF110, is a direct binding target of YM155. The enhanced survivin promoter activity by overexpression of ILF3/NF110 was attenuated by YM155 in a concentration-dependent manner, suggesting that ILF3/NF110 is the physiological target through which YM155 mediates survivin suppression. The results also show that the unique C-terminal region of ILF3/NF110 is important for promoting survivin expression and for high affinity binding to YM155. The American Society for Biochemistry and Molecular Biology 2012-07 /pmc/articles/PMC3394938/ /pubmed/22442257 http://dx.doi.org/10.1074/mcp.M111.013243 Text en © 2012 by The American Society for Biochemistry and Molecular Biology, Inc. Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) applies to Author Choice Articles
spellingShingle Research
Nakamura, Naoto
Yamauchi, Tomohiro
Hiramoto, Masashi
Yuri, Masatoshi
Naito, Masanori
Takeuchi, Masahiro
Yamanaka, Kentaro
Kita, Aya
Nakahara, Takahito
Kinoyama, Isao
Matsuhisa, Akira
Kaneko, Naoki
Koutoku, Hiroshi
Sasamata, Masao
Yokota, Hiroyuki
Kawabata, Shigeki
Furuichi, Kiyoshi
Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
title Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
title_full Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
title_fullStr Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
title_full_unstemmed Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
title_short Interleukin Enhancer-binding Factor 3/NF110 Is a Target of YM155, a Suppressant of Survivin
title_sort interleukin enhancer-binding factor 3/nf110 is a target of ym155, a suppressant of survivin
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394938/
https://www.ncbi.nlm.nih.gov/pubmed/22442257
http://dx.doi.org/10.1074/mcp.M111.013243
work_keys_str_mv AT nakamuranaoto interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT yamauchitomohiro interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT hiramotomasashi interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT yurimasatoshi interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT naitomasanori interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT takeuchimasahiro interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT yamanakakentaro interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT kitaaya interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT nakaharatakahito interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT kinoyamaisao interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT matsuhisaakira interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT kanekonaoki interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT koutokuhiroshi interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT sasamatamasao interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT yokotahiroyuki interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT kawabatashigeki interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin
AT furuichikiyoshi interleukinenhancerbindingfactor3nf110isatargetofym155asuppressantofsurvivin